High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry

Nature Protocols

Volumn 3, Issue 9, 2008, Pages 1476-1484

  Hong, Sun Pyo ^a   Shin, Soo Kyung ^a   Lee, Eun Hee ^b   Kim, Eun Ok ^a   Ji, Seung Il ^a   Chung, Hyun Jae ^a   Park, Sun Nie ^c   Yoo, Wangdon ^a   Folk, William R ^d   Kim, Soo Ok ^a  

^a GeneMatrix Inc   (South Korea)

^b Green Cross Reference Laboratory   (South Korea)

^c Korea Food and Drug Administration   (South Korea)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CONTROLLED STUDY; DNA CLEAVAGE; ENZYME LOCALIZATION; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENOMIC FRAGMENT; GENOTYPE; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; WART VIRUS;

BASE PAIRING; BASE SEQUENCE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

HUMAN PAPILLOMAVIRUS;

EID: 51649100313     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2008.136     Document Type: Article

References (40)

1. Muñoz, N. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527 (2003).
2. Chow, V.T., Loh, E., Yeo, W.M., Tan, S.Y. & Chan, R. Identification of multiple genital HPV types and sequence variants by consensus and nested type-specific PCR coupled with cycle sequencing. Pathology 32 204-208 (2000).
3. Laconi, S. et al. One-step detection and genotyping of human papillomavirus in cervical samples by reverse hybridization. Diagn. Mol. Pathol. 10, 200-206 (2001).
4. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithetial Lesions Triage Study (ALTS) Group. J. Natl. Cancer Inst. 92, 397-402 (2000).
5. Terry, G. et al. Detection of high-risk HPV types by the hybrid capture 2 test. J. Med. Virol. 65, 155-162 (2001).
6. Schiffman, M.H. et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst 85, 958-964 (1993).
7. Walboomers, J.M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
8. Bulkmans, N.W., Rozendaa, L., Voorhorst, F.J., Snijders, P.J. & Meijer, C.J. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br. J. Cancer 92, 1800-1802 (2005).
9. Clavel, C. et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br. J. Cancer 90, 1803-1808 (2004).
10. Haff, L.A. & Smimov, I.P. Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. Genome Res. 7, 378-388 (1997).
11. Laken, S.J. et al. Genotyping by mass spectrometric analysis of short DNA fragments. Nat. Biotechnol. 16, 1352-1356 (1998).
12. Ross, P., Hall, L., Smimov, I.P. & Haff, L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat. Biotechnol. 16 1347-1351 (1998).
13. Abdi, F., Bradbury, E.M., Doggett, N. & Chen, X. Rapid characterization of DNA oligomers and genotyping of single nucleotide polymorphism using nucleotide-specific mass tags. Nucleic Acids Res. 29, 61 (2001).
14. Wolfe, J.L. et al. A genotyping strategy based on incorporation and cleavage of chemically modified nucleotides. Proc. Natl. Acad. Sci. USA 99, 11073-11078 (2002).
15. Mauger, F. et al. SNP genotyping using atkati cleavage of RNA/DNA chimeras and MALDI time-of-flight mass spectrometry. Nucleic Acids Res. 34, e18 (2006).
16. Sauer, S., Reinhardt, R., Lehrach, H. & Gut, I.G. Single-nucleotide polymorphisms: Analysis by mass spectrometry. Nat. Protoc. 1 1761-1771 (2006).
17. Stuyver, L. et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38, 702-707 (2000).
18. Stuyver, L., Wyseur, A., van Arnhem, W., Hernandez, F. & Maertens, G. Second-generation line probe assay for hepatitis C virus genotyping. J. Clin. Microbiol. 34, 2259-2266 (1996).
19. Kim, H.S. et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir. Ther. 10, 441-449 (2005).
20. Hong, S.P. et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 40, 837-844 (2004).
21. Kim, Y.J. et al. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin. Chem. 51 1123-1131 (2005).
22. Szybalski, W., Kim, S.C., Hasan, N. & Podhajska, A.J. Class-IIS restriction enzymes-a review. Gene 100, 13-26 (1991).
23. Lee, C.H. et al. Predominance of hepatitis B virus YMDD mutants is prognostic of virat DNA breakthrough. Gastroenterology 130, 1144-1152 (2006).
24. Yeon, J.E. et al. Resistance to adefovir dipivoxil in lamivudine-resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55, 1488-1495 (2006).
25. Paik, Y.H. et al. Clinical impact of early detection for YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir. Ther. 11, 447-455 (2006).
26. Lee, Y.S. et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43, 1385-1391 (2006).
27. Chung, H.J. et al. Comparison of efficacy of human papilloma virus genotyping assays using restriction fragment mass polymorphism and DNA chip analysis in patients with abnormal pap smear and uterine cervical cancer. Korean J. Pathol. 40, 439-347 (2006).
28. Lee, E.H. et al. Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays. Korean J. Lab. Med. 27 62-68 (2007).
29. Ahn, S.H. et al. Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J. Med. Virol. 78, 1564-1571 (2006).
30. Hwang, S.H., Oh, H.B., Choi, S.E., Hong, S.P. & Yoo, W. Effective screening of informative single nucleotide polymorphisms using the novel method of restriction fragment mass polymorphism. J. Int. Med. Res. 35, 827-835 (2007).
31. Sohn, S.K. et al. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leuk. Lymphoma 48, 1659-1661 (2007).
32. Smirnov, I.P., Hall, L.R., Ross, P.L. & Haff, L.A. Application of DNA-binding polymers for preparation of DNA for analysis by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 15, 1427-1432 (2001).
33. Little, D.P. et al. MALDI on a chip: Analysis of arrays of low-femtomole to subfemtomote quantities of synthetic oligonucleotides and DNA diagnostic products by a piezoelectric pipet. Anal. Chem. 69, 4540-4546 (1997).
34. Shahgholi, M., Garcia, B.A., Chiu, N.H., Heaney, P.J. & Tang, K. Sugar additives for MALDI matrices improve signal allowing the smallest nucleotide change (A:T) in a DNA sequence to be resolved. Nucleic Acids Res. 29, egi (2001).
35. Wu, K.J., Steding, A. & Becker, C.H. Matrix-assistedlLaser desorption time-of-flight mass spectrometry of oligonucleotides using 3-hydroxypicolinic acid as an ultraviolet-sensitive matrix. Rapid Commun. Mass Spectrom. 7, 142-146 (1993).
36. Kim, Y., Hurst, G.B., Doktycz, M.J. & Buchanan, M.V. Improving spot homogeneity by using polymer substrates in matrix-assisted laser desorption/ionization mass spectrometry of oligonucleotides. Anal. Chem. 73, 2617-2624 (2001).
37. Gravitt, P.E. et al. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38, 357-361 (2000).
38. Kwok, S. & Higuchi, R. Avoiding false positives with PCR. Nature 339, 237-238 (1989).
39. Wright, T.C. et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287, 2120-2129 (2002).
40. Fontaine, V. et al. Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J. Clin. Microbiol. 45, 928-934 (2007).